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Abstract
A universal cancer biomarker candidate for diagnosis is supposed to distinguish, within a broad range of tumors, between
healthy and diseased patients. Recently published studies have explored the universal usefulness of some biomarkers in
human tumors. In this study, we present an integrative approach to search for potential common cancer biomarkers. Using
the TFactS web-tool with a catalogue of experimentally established gene regulations, we could predict transcription factors
(TFs) regulated in 305 different human cancer cell lines covering a large panel of tumor types. We also identified
chromosomal regions having significant copy number variation (CNV) in these cell lines. Within the scope of TFactS
catalogue, 88 TFs whose activity status were explained by their gene expressions and CNVs were identified. Their minimal
connected network (MCN) of protein-protein interactions forms a significant module within the human curated TF
proteome. Functional analysis of the proteins included in this MCN revealed enrichment in cancer pathways as well as
inflammation. The ten most central proteins in MCN are TFs that trans-regulate 157 known genes encoding secreted and
transmembrane proteins. In publicly available collections of gene expression data from 8,525 patient tissues, 86 genes were
differentially regulated in cancer compared to inflammatory diseases and controls. From TCGA cancer gene expression data
sets, 50 genes were significantly associated to patient survival in at least one tumor type. Enrichment analysis shows that
these genes mechanistically interact in common cancer pathways. Among these cancer biomarker candidates, TFRC, MET
and VEGFA are commonly amplified genes in tumors and their encoded proteins stained positive in more than 80% of
malignancies from public databases. They are linked to angiogenesis and hypoxia, which are common in cancer. They could
be interesting for further investigations in cancer diagnostic strategies.
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Introduction
Cancer is a multifactorial disease. Many cancer types and stages
have been distinguished. This complexity makes the quest for
‘‘universal cancer biomarkers’’ a challenging task. However, many
studies conducted separately on different cancer types have
reported common genes with potential biomarker value in
treatment or diagnosis [1].
On the basis of literature reviewing or by using high-throughput
techniques some authors identified potential biomarkers common
to several cancers and tried to develop strategies to identify them
from patient biofluids either directly or indirectly. Among these
markers, telomerase has been reported as being highly expressed
in neoplasms [2]. A platform to capture circulating tumor cells
from patient blood and measure their telomerase activity has been
proposed as a cancer diagnostic tool [3]. In addition, extra-cellular
cAMP-dependent protein kinase A (EC-PKA) has been reported
to be a good marker for multiple cancers [4]. Auto-antibodies
against EC-PKA measured by ELISA from patients sera have
been found to be highly specific to cancer [5]. Follicle-stimulating
hormone (FSH) receptor was also reported to be selectively
expressed in a variety of tumors [6]. The same observations apply
also to a cytochrome P450 (CYP1B1) [7]. Epigenetic alterations, in
addition, could have a diagnostic value in cancer. Indeed, some
authors have pointed to cancer-specific DNA methylation patterns
as a marker for malignant diseases [8]. They can be detected on
cell-free circulating DNA in the blood [9]. Auto-antibodies against
leukocyte antigen F (HLA-F) were also detected in patients with
various cancer types compared to healthy individuals [10].
Cancer biomarker candidate genes could be identified from
literature. Confidence weights can be associated to each gene
using its citation frequency [11]. Although initially used to
enumerate markers specific to each cancer type, these weighted
lists can help selecting common biomarkers in cancer. However,
more elaborated strategies have been used to identify common
cancer biomarkers, including gene expression meta-analysis across
different tumor types [12,13]. They can be associated with
function and pathway annotation enrichment filters to select
common biomarkers [14].
In this study, we have elaborated an integrative strategy to
search for useful biomarkers common to cancer types. Our
working hypothesis is based on the assumption that almost all the
perturbations that lead to malignancy transformation of normal
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pathways [15]. In general, these pathways might end by activating
and/or repressing some sets of genes. These genes are targets of
transcription factors (TFs). Some of these TFs are redundantly
modulated between different cell transforming events [16–22].
They could be seen as connections or cross-talk nodes of the
cancer leading pathways [23–27]. Thus, there should be a set of
minimal connected TFs commonly perturbed in tumors as they
share modulated pathways [28]. This set of TFs could be
considered as a bottleneck of cancer pathways. If common cancer
biomarkers exist, they are more likely to be among the targets of
these commonly regulated TFs [29]. In this study, we took
advantage of TFactS, a tool that we recently developed to predict
TF regulations from high throughput gene expression data [30].
Results
Identification of TFs Regulated in Cancer Cell Lines
Gene expression and SNP data were available for 305 cell lines,
from which results were further analyzed. These cell lines
represent a broad panel of cancer types covering 28 different
histological sites.
We assumed that important TFs would be those for which gene
expression and CNV could explain their activity status [31,32].
They could be identified using the regression model shown in
Figure 1. To compute all the parameters needed for this model, we
identified genes differentially regulated in each cell line compared
to the pool of all other cell lines. The median number of regulated
genes per cell line is 218 (min: 15 and max: 721), cumulatively
involving 4,686 unique known coding genes. Then, each cell line-
specific gene list was submitted to TFactS and compared against
catalogue of experimentally validated TF target genes using
Fisher‘s test [30]. We have shown that this tool efficiently predicts
TF regulation from regulated gene lists [33,34]. On the other
hand, the SNP data were normalized and segmented then
submitted to the GISTIC algorithm to identify chromosomal
regions significantly altered in all these cell lines [35]. Figure S1
shows that significant amplifications and deletions were spread in
the whole genome. A restricted analysis of TF-encoding genes
revealed that 2,113 of the 2,335 genes known to encode ‘‘DNA
binding’’ proteins (GO term) had their loci significantly altered, at
least, in one cell line. To select transcription factors relevant to
cancer in a more stringent manner, we combined the analysis on
expression, activity and CNV (Figure 1).
For each TF, correlation profiles with other TFs were computed
based on: regulation (inferred from TFactS analysis), gene
expression and genomic alterations (CNV), respectively. The
model in Figure 1 uses these correlation scores to find significant
TFs, for which gene expression associated to CNV could explain
the corresponding inferred regulation. 88 TFs were identified (p-
values ,=0.05, Table S1). Supporting our results, CNV affecting
some of these TFs in cancer have already been reported,
including: TP53, BRCA1, RUNX1 and MYC [36].
The Minimal Connected Network of Transcription Factors
Regulated in Cancer Cell Lines
We used the Snow web tool to identify the minimal connected
network (MCN) of protein-protein interactions involving the 88
TFs associated to cancer from our initial analysis. Snow
predicted this MCN by computing the shortest paths linking
the input proteins either directly or with one tolerated
intermediate protein, based on a built-in database of human
protein-protein interactions [37,38]. Restricting our Snow-based
analysis to the human protein interactome with at least two
Figure 1. A workflow summarizing the strategy to identify
accessible common cancer biomarkers. See text for details. Reg:
regulation; Exp: expression; CNV: copy number variation; MCN: minimal
connected network; PPI: protein-protein interactions; TF: Transcription
factor.
doi:10.1371/journal.pone.0039666.g001
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connecting 70 out of 88 TFs either directly or with one
intermediate. It is remarkable that most of the TFs identified in
the first step could be linked in this single protein-protein
interaction subnetwork. Eighteen TFs were lost due to our
restrictions in the analysis or to their absence in the Snow-
annotated interactome. Snow uses Kolmogorov-Smirnov’s test to
evaluate the significance of the identified subnetwork by
comparing its betweenness, connections and clustering coefficient
distributions to those generated from 1,000 random networks
with the same number of proteins. Our identified subnetwork
had significant p-values for all these evaluated parameters
(betweenness: 2.06E237, connections: 1.68E247, clustering
coef.: 4.07E243). This subnetwork contained two distinct
connected components. The first contained almost all interac-
tions of the significant subnetwork and was considered as the
cancer cell line-associated TFs MCN for subsequent analysis
(Figure 2). The second connected component, which has only
two interactions linking three proteins was discarded.
We then asked whether false positives from TFactS, GISTIC
and differential expression analyses could affect the MCN
identification. To control these effects, we performed a negative
control, in which we analyzed 100 different random lists of 88 TFs
from the TFactS catalogue. Each list was submitted to Snow to
produce a MCN using the same parameters as above. By
comparing the distribution of the betweenness scores from all
the random MCNs to the established MCN from our model, we
found a significant difference (p-value ,0.01; KS test). Together
with the results discussed above from the built-in comparison with
1,000 random networks performed in Snow, this suggested that
our identified MCN constitutes a significant module involving TFs
commonly regulated in cancer cell lines.
This MCN might be viewed as a regulatory ‘‘round-about’’ of
the majority of regulated pathways in cancer cell lines. Indeed, as
depicted in Figure 3, many MCN proteins are involved in many
Figure 2. The minimal connected network of TFs regulated in cancer cell lines. The Snow web tool identified a significant human curated
protein-protein interaction subnetwork involving 70 out of the 88 TFs correlatively regulated in cancer cell lines. The first connected component as
shown here is considered as the minimal connected network (MCN) connecting these TFs. Each node represent a protein. Edges are the protein-
protein interactions validated by at least two experimental evidences. Nodes shaded in violet represent the top ten most central TFs in the MCN.
Node-ranking was based on the betweenness centrality scores.
doi:10.1371/journal.pone.0039666.g002
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proteins are also significantly involved in immune response
pathways. This could reflect an involvement of some MCN TFs
like NFKB in both cancer and inflammation [16].
Target Genes of MCN Central Transcription Factors
Transcription factors in the minimal connected network
identified above likely represent the main regulatory effectors
commonly perturbed in the analyzed cancer cell lines. We focused
on the most central TFs in this network. Centrality of nodes in a
given network could be estimated using many parameters. Among
them, betweenness scores the frequency by which a certain node is
within the shortest paths linking any other two nodes. It is thought
to be a good estimate of centrality [39]. By top-ranking the 236
MCN nodes according to their betweenness scores, we identified
59 central proteins having scores above the average. These central
proteins show the same functional enrichment as the whole MCN.
We arbitrarily selected the top 10 central MCN nodes. Their
encoding gene names are: TP53, ESR1, CREBBP, MYC, AR,
BRCA1, RELA, RARA, EP300 and NFKB2. These ten TFs
concentrate 41% of the total betweenness cumulative scores of the
236 MCN nodes. They could be considered as hubs or collectors
of these network interactions. This is in line with the ‘‘scale free’’
model that was suggested to govern the TF protein-protein
interactions, in which the hubs were built around TFs associated
with malignancies [40]. We argued that common cancer
biomarkers are likely to be found among the targets of these most
central TFs. 874 unique target genes of these ten TFs are reported
in the TFactS catalogue. An enrichment analysis of these genes,
using ‘‘genetic association db disease’’ in the DAVID web tool,
revealed an over-representation of a large panel of cancer types as
well as ontologies related to immune responses and inflammatory
diseases (File S1).
Figure 3. Signaling pathway enrichment in the MCN proteins. All proteins (nodes) in the MCN were submitted to DAVID web tool for KEGG
pathway enrichment analysis. Significant pathways are shown by categories according to the 2log10(p-value) and the percentage of intersection
between the submitted list and queried annotations.
doi:10.1371/journal.pone.0039666.g003
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Transcription Factors
Enrichment analysis performed on MCN proteins as well as the
targets of the central TFs showed an association between cancer
and inflammation. This association is well documented in
literature [41]. Cancer-specific biomarkers have to be differentially
expressed in cancer patients compared to healthy individuals and
patients with inflammatory diseases [42]. In addition, a universal
cancer biomarker should be cancer-specific in a broad panel of
tumor types. Since our interest is to identify ‘‘accessible’’ cancer
biomarkers, we sought to restrict further analysis only on genes
coding for secreted and transmembrane proteins. The SP-PIR
annotation keywords database, as used in the DAVID tool,
contains 1,689 and 642 genes annotated as encoding secreted and
transmembrane proteins, respectively. In the 874 target genes of
the ten most central TFs in the MCN, we found 57 genes encoding
secreted proteins (p-value: 1.1E26) and 110 encoding transmem-
brane proteins (p-value: 4.3E25). This represents a unique set of
157 genes. Thus, identifying the TFs MCN and focusing on target
genes of the ten most central TFs allowed us to prioritize a short
list of accessible proteins to be analyzed in patient samples for
differential expression (Figure 1).
We further filtered this gene list using available patient data. We
performed gene expression analysis on an assembled microarray
large data set of 8,525 different tissues from patients with cancer or
inflammation and healthy individuals (Figure 4, File S2). From the
prioritized 157 genes, we could establish a list of 86 cancer-specific
transcripts (Figure 4). Among them, 3 genes were approved by
FDA for cancer diagnosis, including: EGFR, KLK3 (PSA) and
AFP for the diagnosis of colon, prostate and testis cancers,
respectively [43]. Moreover, HLA-F in this list has already been
reported as detectable in the serum of various cancer patients
using indirect ELISA [10].
Potential Biomarkers Common in Cancer
In order to strengthen the likelihood to find potential
common biomarkers among the cancer-specific gene list
(Figure 5), we filtered these genes based on their significant
effect on patient survival in any of the cancer types from
TCGA database. The available gene expression data sets from
TCGA, covering nine cancer types, were downloaded and
analyzed separately for gene-survival association. For each gene,
patients were divided in three groups (tertiles) according to the
expression levels of the studied gene. Groups of patients with
low, intermediate and high expression were then obtained.
Making use of the available patient survival data: follow up
duration and death status, we fitted Kaplan-Meier curves to
these groups. Genes predicting patient survival significantly (log-
rank p-value ,=0.05), in at least one cancer type, are shown
in Table S2. The products of these 50 genes mediate many
interacting pathways in cancer, as depicted in Figure S2
(KEGG pathway enrichment, p-value ,4.29E24).
For each gene listed in Table S2, we added the following
resources: (i) CNV significantly affecting the corresponding gene
loci in all tumor types as analyzed in the Tumorscape database
[44]; (ii) percentage of immunohistochemical (IHC) positive
staining in cancer as detected in ProteinAtlas database [45]. We
considered that genes positive for all criteria listed in Table S2 are
more likely to be common cancer biomarker candidates. TFRC,
VEGFA and MET are the best potential candidates. These genes
have been separately associated to many cancer types in literature
(Table S3).
Discussion
Cancer types have been screened separately for biomarker
identification. Nowadays, there is an emerging effort to search for
universal cancer markers. The recently available high-throughput
data from cancer patient specimens make this task more affordable
in the context of integrative analysis. This study was done within
such a framework.
Cancer is a multistage disease, in which normal cells are
progressively transformed to malignant ones. This process
involves transcription factor (TF) regulation to ensure the
transcription of needed genes [46]. We assumed that TFs
regulated in cancer would have their activity explained by their
coding gene expression level and genomic alterations. We
hypothesized that cancer-associated TFs could interact together
in a modular manner, such that cancer-triggering events end up
perturbing the function of this module. Biomarkers common to
many cancer types could be among these TF target genes. We
then followed the workflow depicted in Figure 1 to target
important genes commonly regulated in cancer that encode
accessible proteins. We assumed that focusing on TFs will guide
us to find the most valuable part of cancer information, which
could be measured by gene expression [47]. Adding CNV data
to filter important TFs will strengthen this approach. Whereas,
analyzing all regulated genes and significantly altered chromo-
somal regions without any contextualization in terms of
regulators (TFs) will dilute the common cancer biomarker
among many false positive outcomes.
As a first step in our quest for common cancer biomarkers, we
tried to identify the minimal connected network involving TFs, the
activity of which is regulated in tumors. We integrated genomics
and transcriptomics data from a panel of cancer cell lines, together
with inferred TF regulation from gene expression using TFactS,
which has been shown previously to be able to infer accurately TF
regulation or activity status from a list of expressed genes [30]. The
use of cell lines in this step is justified by the availability of both
genomic and expression data. In addition, building meaningful
MCN requires data from homogeneous cells, which is not the case
of most primary cancer samples, in which genomic alterations and
gene expression differ between cancer cells and stromal cells, and
even between different cancer cell clones. We identified 88 TFs,
which could be the main regulators in cancer cell lines. This step
is, however, limited by the TFs represented in TFactS, although
they sample the most studied TFs in literature. This step could also
be ameliorated by taking into account other genomic alterations,
such as mutations. However, whole genome alteration data were
not available yet for all the studied cell lines.
By protein-protein interaction analysis, MCN connecting the
majority of the 88 TFs has been identified from the curated human
proteome network. The MCN contains both TFs and other
proteins. Enrichment analysis revealed that this MCN assembles
major known pathways driving multiple cancer types. Strikingly,
immune response pathways were also enriched in MCN, which
was identified based on cell line data, discarding any tumor micro-
environmental effect on these results. This suggests a dual role
played by this module of connected TFs in both cancer and
inflammation. Results from our negative control procedure
suggested that the cancer-associated MCN forms a significant
module. This module’s most central TFs are susceptible to act as
the main ‘‘collectors’’ of marginal perturbations.
In a second step, we arbitrarily limited our analysis to target
genes of the top ten most central MCN TFs. Enrichment analysis
of these genes revealed a cancer context pathways over-
representation, as expected. Since our purpose was to identify
Biomarkers Common to Different Cancer Types
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list to 157 genes coding for secreted and transmembrane proteins.
By comparing their expression in a panel of 8,525 patients, we
identified a set of 86 cancer-specific genes differentially expressed
in cancer versus normal and inflammation phenotypes. They
include three out of six proteins approved by FDA in specific
cancer diagnosis: PSA/KLK3, EGFR and AFP. Expression of
these three genes could be checked in other cancer types. PSA,
prostate specific antigen, for instance, although widely used in
prostate cancer diagnosis, it was also reported in kidney, stomach
and breast cancers [48–50]. These results provide an internal
validation of our methodology.
We sought to further restrict the analysis by taking into account
the potential prognostic value in at least one cancer type. This was
performed by associating gene expression to patient survival in
TCGA data sets. 50 genes significantly predicted survival in at
least one cancer type. Each of these genes could be investigated
separately in the corresponding cancer type for prognosis. These
genes are significantly involved and interconnected in many
cancer pathways (Figure S2). Nevertheless, immunomodulatory
Figure 4. Patient sample repartition and cancer-specific gene expression analysis. Microarray gene expression data representing 8,525
patients samples were downloaded from GEO. A- 78% of patients had different cancer types; 14% are healthy individual and were sampled from
different tissues; 8% of patients had inflammation/sepsis and were investigated from the whole blood and other tissues. B- differential expression of
the MCN top ten central TFs target gene list coding for secreted and transmembrane proteins were analyzed. Among these genes, as shown in the
Venn-diagram, 140 probe sets (86 unique genes) were found to be cancer-specific. GI: Gastro-intestinal.
doi:10.1371/journal.pone.0039666.g004
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which might suggest that some of these genes may not fully
distinguish patients with cancer from those with inflammatory
diseases.
We identified three potential biomarkers common to cancer, i.e.
TFRC, VEGFA and MET as evidenced by: (i) gene over-
expression in cancer compared to normal and inflammation; (ii)
gene expression significantly linked to patient survival in at least
two cancer types; (iii) corresponding CNV focally significantly
amplified in tumors; (iv) proteins stain positive in more than 80%
of cancers. VEGFA promotes angiogenesis. Its diagnostic potential
was investigated separately in many cancer types (Table S3).
MET, is a known oncogenic tyrosine kinase receptor for
hepatocyte growth factor. It is also associated with many cancer
types (Table S3). In addition, it has been reported as a marker for
cancer stem cells in: prostate, head and neck, liver, brain and lung
cancers [51–56]. VEGFA and MET synergy in angiogenesis might
be targeted for more effective anti-tumoral therapy [57]. TFRC,
transferrin receptor, is known to be expressed in many tumor types
(Table S3). Expression of VEGFA and TFRC is commonly
regulated by HIF and MYC, which promote angiogenesis and
proliferation, respectively [58–60]. The connection between these
two TFs via their target genes is known to confer a metabolic
advantage to tumors under hypoxia, which is a common condition
in malignant diseases [61,62].
In summary, our strategy identified a network of TFs that
regulate 50 potential common cancer biomarkers. Currently
available data in TCGA, Tumorscape and ProteinAtlas databases
pointed to VEGFA, TFRC and MET genes as potential
candidates. Literature knowledge associated to these genes
corroborates our approach. Taken together, all these observations
might suggest to further investigate the usefulness of VEGFA,
MET and TFRC as common cancer biomarkers. This could be
performed by direct detection of these biomarkers or by checking
for the presence of auto-antibodies directed against potential
cancer proteins in patient serum, an approach that has gained
much interest in the cancer diagnosis field [4,63].
Materials and Methods
Microarray Analysis
The data from 950 microarrays performed by GlaxoSmithKlein
laboratories (GSK) on different cancer cell lines were downloaded
from arrayExpress (E-MTAB-37). The RMA normalization
method was applied using the xps package from R/Bioconductor
[64]. Gene expression on each cell line was performed on
duplicates or triplicates. Kolmogorov-Smirnov’s test was per-
formed to select genes differentially expressed in each cell line
compared to others. A Bonferroni correction threshold was
applied on p-values. Genes with an e-value ,=10 were
considered as significantly differentially expressed on the corre-
sponding cell line.
Transcription Factor Regulation Analysis
Each gene list regulated in each cell line was submitted to
TFactS to predict regulated TFs [30]. TFactS sign less catalogue
(version 2) contains 6,823 regulations linking 345 unique TFs to
their 2,650 unique gene targets. For each list of regulated genes,
TFactS predicts the TFs whose targets are enriched in the
submitted lists using Fisher’s test. In this study, the larger sign-less
catalogue was used instead of the restricted sign-sensitive one.
TFactS was executed using BatchTFactS default parameters
(www.tfacts.org). TFs with a positive e-value score (2log10(e-
value)) were considered as significant. TFs that were not significant
in all cell-lines were discarded before the model fitting.
Genomic Copy Number Variation Analysis
The genomics data of the above cell lines were also released by
GSK. SNP arrays data sets available on arrayExpress were
downloaded (E-MTAB-38). They were analyzed using the aroma-
affymetrix package on R/Bioconductor [65]. Briefly we applied a
quantile normalization followed by the CRMA summarization
and corrected for chip and PCR fragment length effects [66].
Then the GLAD algorithm was applied to raw copy numbers for
segmentation [67]. The segmented data were then submitted to
GISTIC algorithm to find significantly altered regions in all
chromosomes except X and Y. A default q-value threshold of 0.25
was used to select significant regions [35]. Prior to CNV-based
correlation matrix computing and the model fitting, CNV values
for each gene in the significantly altered chromosomal regions
were normalized as follows: (i) for each of the GISTIC-reported
significant regions, we determined the median value of the
significant CNV peaks; (ii) each gene in a significant chromosomal
region has been assigned the value of this median. The values of
the CNV were in log2-ratio as outputted by GISTIC. The
chromosomal location of genes was obtained using the Ensembl
genes 64 database with human ‘‘GRCH37.p5’’ release in Biomart
web tool [68].
Identification of the Minimal Connected TF Regulated in
Cancer Cell Lines
In order to identify a set of correlated TFs that are commonly
regulated in cancer, we considered 305 cell lines, for which both
expression and SNP data were available. Each TF has three
measurements in each cell line: TF regulation scores estimated by
TFactS (2log10(e-value)), TF-encoding gene expressions (from
microarrays) and TF-locus copy number variations (from median
normalized GISTIC analysis). Three matrices, with TFs in rows
and cell-lines in columns, could be built from these data: a TF
regulation matrix, a TF-encoding gene expression matrix and a
TF-locus CNV matrix. In each of these matrices, we computed
correlations of each TF with the other TFs using Pearson
correlation coefficient. These correlations could be represented
as TF-TF correlation profiles. Then we fitted the following model
for each TF: R=b0+ b1*E + b2*C, Where:
(R) TF-TF correlation profile based on TFactS scores, only TFs
significantly regulated in at least one cell line were used; (E) TF-TF
correlation profile based on gene expression; (C) TF-TF correla-
tion profile from significant regions identified by GISTIC
algorithm, these correlations were computed using loci copy
number variation median-normalized values.
Each TF having significant b1 (p-value ,=0.05) and b2 (p-
value ,=0.05) was considered as correlatively regulated in
cancer. For these TFs, there is an effect of gene expression and
genomic alteration (CNV) on their regulation.
Figure 5. Significant cancer-specific biomarkers from patient gene expression analysis. Cancer-specific gene expression significance and
fold change. Significance was attested by B-H p-value correction, and all shown genes have B–H p-value,=0.05. Bar-plots show the
2log10(uncorrected p-value). Triangles show the logged fold change of the corresponding gene in cancer compared to healthy and inflammation
patient phenotypes. FDA approved cancer biomarkers are marked with (*).
doi:10.1371/journal.pone.0039666.g005
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tool to identify their minimal connected network [38]. The
SNOW parameters were set as follows: curated human protein-
protein interactome with at least two experimental evidences,
1,000 random networks for significance, only one extension
interaction was allowed to connect the submitted proteins. A built-
in mapping was performed by Snow between submitted gene
names and the network protein names.
MCN Protein-protein Interaction Network Analysis
Network analysis was done using Cytoscape [69]. MCN node
centrality analysis was computed using CentiScaPe plugin.
Proteins were ranked according to highest betweenness [39].
Target genes of the top ten ranked TFs were kept for further
analysis.
MCN Negative Control
From the list of all TFs represented in TFactS sign-less
catalogue, we generated 100 random lists containing 88 distinct
elements. These 100 random lists were submitted to Snow web
tool using the same parameters as above. The betweenness
distribution of the identified cancer-related MCN was compared
to the distribution of the whole random MCNs using Kolmogorov-
Smirnov’s test in R. The betweenness scores used here are from
Snow output.
Functional Enrichment Analysis
The DAVID web tool was used to perform a functional analysis
of the selected target genes [70]. A p-value threshold of 0.05 was
used for significance.
Cancer Patients Gene Expression Analysis
Data from 8,525 patient samples analyzed with HG-
U133A2Plus microarrays were downloaded from GEO database.
Patient categories were distributed as follows: 78% cancer, 8%
inflammation and 14% healthy. Expression data were log2-
transformed then normalized per gene by subtracting the gene
median expression and dividing by the inter-quartile-range of its
expression vector. This data set was used to compare gene
expression profiles of genes significantly annotated as coding for
secreted or transmembrane proteins using SP-PIR annotation
keywords on DAVID from the known targets of the MCN top ten
central TFs. Genes significantly differentially expressed were
determined between cancer compared to inflammation and
healthy phenotypes on one hand, and between inflammation
compared to cancer and healthy phenotypes on the other hand.
Genes specific to cancer were significantly differentially regulated
in the former comparison but not in the later. Differentially
regulated genes were computed using R/Bioconductor (limma
package) and significance was controlled using B–H correction of
p-value ,=0.05 [64,71]. The cancer-specific gene list identified
from this analysis was considered as the accessible cancer-specific
biomarker list (genes specific to cancer and coding for secreted and
transmembrane proteins).
Survival Analysis
The accessible cancer-specific biomarker list was evaluated for
prognosis potential in different TCGA published cancer data sets.
TCGA database offers a set of gene expression from clinically
annotated patient samples (http://tcga-data.nci.nih.gov/tcga/).
We downloaded (09/27/2011) level2 gene expression data for all
the patients from 9 publicly available cancer types (GBM:
Glioblastoma multiform, OV: Ovarian serous cystadenocarci-
noma, LAML: Acute Myeloid Leukemia, BRCA: Breast invasive
carcinoma, COAD: Colon adenocarcinoma, KIRC: Kidney renal
clear cell carcinoma, LUSC: Lung squamous cell carcinoma,
UCEC: Uterine Corpus Endometrioid Carcinoma). The number
of patients per gene expression data set was distributed as follows:
BRCA: 600; COAD: 179; GBM: 536 (agilent) or 555 (affy);
KIRC: 72; LAML: 197; LUSC: 161 (agilent) or 134 (affy); OV:
608 (agilent) or 590 (affy); READ: 78; UCEC: 54. Survival data
were among the clinical information available for the majority of
these patients. For each gene, in each cancer type, the expression
vector from level2 TCGA data was standardized by median
subtraction and inter-quartile range division. Then each normal-
ized expression vector corresponding to each gene was divided on
three groups (tertiles). Patients in the lower tertile were assigned a
gene down-regulation; patients in the intermediate tertile were
assigned an intermediate gene expression; patients in the upper
tertile were assigned an up-regulation of the gene in interest. The
R/Bioconductor (survival package) was used to fit survival curves
on categorized patients for each gene [72]. Three Kaplan-Meier
survival curves were then fitted for each gene corresponding to up-
regulation, intermediate and down-regulation groups of patients
according to their death status and follow up duration.
Significance of the difference between these curves was estimated
based on the log-rank p-value ,=0.05. If data from more than
one platform was available (Affymetrix or Agilent), the analysis is
done independently on each.
Supporting Information
Figure S1 Copy Number Variation results. Copy Number
Variation GISTIC scores and q-values for the whole cancer cell-
lines data set. Significance profiles (q-values in the bottom and
scores in the top horizontal axes) are shown for chromosomal
regions in the left and right vertical axes of the panels for : A-
amplified regions, B- deleted regions.
(TIF)
Figure S2 Patient survival-affecting genes are involved
in many cross-talking cancer pathways. Genes significantly
affecting cancer patient survival are mechanistically interacting to
trigger important cancer pathways. These genes are enriched (p-
value =4.29E24) in KEGG’s cancer pathways analyzed by
DAVID web-tool.
(TIF)
File S1 Enrichment analysis of the top 10 MCN TF
target genes
(XLS)
File S2 Patient gene expression data sets from GEO
database and their accession numbers.
(XLS)
Table S1 Transcription factors regulated in cancer cell
lines. For each TF, the TF-TF correlations profiles were
determined and the following model was fitted: reg = b0+ b1 *
exp + b2 * cnv. Where, for each TF versus the others: ‘‘reg’’ is the
regulation correlation profile, ‘‘exp’’ is the TF-coding gene
expression correlation profile and ‘‘cnv’’ is the TF coding-gene
locus copy number variation correlation profile.
(PDF)
Table S2 Filtered cancer-specific genes. Significant can-
cer-specific genes identified in patient microarray analysis were
filtered to those that are significantly associated (p-value ,=0.05)
with at least one cancer type survival based on TCGA data. The
resulting gene list is shown here. Tumorscape database gives q-
Biomarkers Common to Different Cancer Types
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39666values for CNV alterations in a large collection of tumors. Based
on the CNV from all tumors pooled together, amplification and
deletion q-values corresponding to the chromosomal locations of
these genes are shown. Whether the loci is focally affected by the
CNV is also shown. ProteinAtlas database contains cancer and
normal tissue IHC staining for proteins with available antibodies.
The percentage of staining in cancer is shown. N.A: not available,
N.S: non-significant; GBM: Gliobastoma mutiforme, OV: Ovar-
ian serous cystadenocarcinoma, LAML: Acute Myeloid Leukemia,
BRCA: Breast invasive carcinoma, COAD: Colon adenocarcino-
ma, KIRC: Kidney renal clear cell carcinoma, LUSC: Lung
squamous cell carcinoma, UCEC: Uterine Corpus Endometrioid
Carcinoma. K-M: Kaplan-Meier log-rank test.
(PDF)
Table S3 Evidences of VEGFA, TFRC and MET associ-
ations to cancer from a non-exhaustive literature
screening.
(PDF)
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